Ernexa Therapeutics Inc.: Form 10-K for the period ended Dec 31, 2013
Filed with the SEC on Mar 31, 2014 and accepted by EDGAR at Mar 31, 2014, 16:14 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2013-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Selling, general and administrative | 12 months2013-01-01 to 2013-12-31 | $16.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2013-01-01 to 2013-12-31 | −$1.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2013-01-01 to 2013-12-31 | $26.0k | us-gaap:InterestExpense |
| Income tax | 12 months2013-01-01 to 2013-12-31 | $46.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2013-01-01 to 2013-12-31 | −$1.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2013-01-01 to 2013-12-31 | −$0.01 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months2013-01-01 to 2013-12-31 | $1.5m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 12 months2013-01-01 to 2013-12-31 | $861.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2013-12-31 | $5.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2013-12-31 | $7.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2013-12-31 | $15.5m | us-gaap:Assets |
| Current liabilities | At period end2013-12-31 | $3.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2013-12-31 | $6.3m | us-gaap:Liabilities |
| Long-term debt | At period end2013-12-31 | $1.6m | us-gaap:LongTermDebt |
| Current portion of debt | At period end2013-12-31 | $631.0k | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2013-12-31 | $9.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001019687-14-001135. Last ingested by Listed: Nov 11, 2026, 02:49 ET. Listed shows no prices and gives no investment advice.